Pallone on supplements
This article was originally published in The Tan Sheet
Recent statements by FDA Commissioner Mark McClellan, MD/PhD, implying a need to "crack down" on dietary supplements "create unnecessary concern among consumers and are grossly unfair to the industry as a whole," Rep. Frank Pallone (D-N.J.) states in Dec. 20 letter to agency head. Referring to McClellan's Dec. 18 announcement of FDA, FTC intentions to target misleading supplement claims, the Congressman notes such statements "give the impression that the entire industry is at fault, rather than those few manufacturers that are not in compliance" (1"The Tan Sheet" Dec. 23, 2002, p. 11). Pallone criticizes FDA's "ineffective and inefficient" attempts to implement DSHEA, requests meeting "to discuss federal legislation regarding" supplements and Congress' expectations for agency...
You may also be interested in...
Dietary supplements marketed to smokers and drinkers are two of nine categories of products that "warrant close scrutiny" for enforcement, FDA says
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.